Follow The Filings

VRCA Verrica Pharmaceuticals Inc.

Health Care, filed as VERRICA PHARMACEUTICALS INC (COM SHS), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 0.0%
  • $145K
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Verrica Pharmaceuticals.

Who owns this now

Largest portfolio weights among holders, up to 0.0% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel Reduce 0.03%

Who owns VRCA

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 0.03%, was 0.19% Reduce −84.5% 23,750 $145K History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VRCA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VRCA insider trades
  • $18.2M bought by 5 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. David Zawitz COO
    Buy
    $30K 6,000 shares at $4.98 +29% to stake
    Traded Aug 17 Filed Aug 18
    ↗
  2. Jayson Rieger CEO
    Buy
    $126K 25,000 shares at $5.03 +14% to stake
    Traded Aug 14–17 Filed Aug 18
    ↗
  3. Noah L. Rosenberg CMO
    Buy
    $31K 6,230 shares at $4.91 +264% to stake
    Traded Aug 17–18 Filed Aug 18
    ↗
  4. John J. Kirby CFO
    Buy
    $25K 5,000 shares at $4.93 +26% to stake
    Traded Aug 18 Filed Aug 18
    ↗
  5. David Zawitz COO
    Buy
    $42K 10,000 shares at $4.24 +91% to stake
    Traded Nov 25, 2025 Filed Nov 25, 2025
    ↗
  6. Jayson Rieger CEO
    Buy
    $400K 94,311 shares at $4.24 +107% to stake
    Traded Nov 25, 2025 Filed Nov 25, 2025
    ↗
  7. Noah L. Rosenberg CMO
    Buy
    $10,000 2,357 shares at $4.24 New stake
    Traded Nov 25, 2025 Filed Nov 25, 2025
    ↗
  8. John J. Kirby CFO
    Buy
    $15K 3,536 shares at $4.24 +65% to stake
    Traded Nov 25, 2025 Filed Nov 25, 2025
    ↗
  9. Paul B Manning Director
    Buy
    $17.5M 4,126,142 shares at $4.24
    Traded Nov 25, 2025 Filed Nov 25, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 5.02 Filing Doc
424B3 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D — Filing Doc
8-K 1.01,3.02,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $5.12M $7.57M —
Gross profit * $4.62M $4.97M —
Gross margin * 90.2% 65.6% —
Net income -$67M -$76.58M -$17.89M
Net margin * -1307.5% -1012.1% —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $77.53M $51.18M $42.54M
Total non-current assets * $4.07M $2.96M $4.59M
Total assets $81.6M $54.13M $47.13M
Total current liabilities $17.02M $29.01M $16.44M
Total non-current liabilities * $44.81M $34.98M $5.95M
Total equity $19.76M -$9.86M $24.74M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$38.58M -$60.93M -$17.63M
Cash from investing -$362,000 -$19,000 $0.00
Cash from financing $74.21M $37.73M $1.44M
Net change in cash $35.27M -$23.22M -$16.18M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.